ES2104853T3 - Composiciones antitumorales y procedimiento de tratamiento. - Google Patents

Composiciones antitumorales y procedimiento de tratamiento.

Info

Publication number
ES2104853T3
ES2104853T3 ES92311031T ES92311031T ES2104853T3 ES 2104853 T3 ES2104853 T3 ES 2104853T3 ES 92311031 T ES92311031 T ES 92311031T ES 92311031 T ES92311031 T ES 92311031T ES 2104853 T3 ES2104853 T3 ES 2104853T3
Authority
ES
Spain
Prior art keywords
hydrogen
halo
compounds
antitumoral
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92311031T
Other languages
English (en)
Inventor
James Jeffry Howbert
James Edward Ray
John Eldon Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2104853T3 publication Critical patent/ES2104853T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ESTA INVENCION PRESENTA CIERTOS COMPUESTOS DE N-FENIL-N''FENILSULFONILUREAS SUSTITUIDAS QUE TIENEN LA FORMULA EN DONDE: X1 ES HALO, CH3 O CF3; X2 ES HIDROGENO, HALO O CF3 SIEMPRE Y CUANDO AL MENOS UNO DE ENTRE X1 Y X2 SEA HALO; A, B, D Y E SE (A) SELECCIONAN INDEPENDIENTEMENTE DEL GRUPO QUE CONSISTE EN HIDROGENO, METILO, ETILO, CLORO, BROMO Y YODO SIEMPRE Y CUANDO NO MAS DE UNO ENTRE A, B, D Y E SEA HIDROGENO O (B) E ES HIDROGENO Y UNO DE ENTRE A, B O D SE SELECCIONA DEL GRUPO QUE CONSISTE EN -NH2, -NHCH3, -N(CH3)2, -N(CH3)(CH2CH3), N(CH2CH3)2 O -OCH3 Y EL RESTO DE ENTRE A, B O DE SELECCIONA DE (A) O (C) E ES HIDROGENO Y A Y B O B Y D JUNTOS SON -(CH2)N O CH=CH(CH2)N-2 DONDE N ES 3 O 4 O -(CH=CH)2O(CH2)QO NA DE (A); O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS Y FORMULACIONES FARMACEUTICAS QUE UTILIZAN ESTOS COMPUESTOS. ESTA INVENCION PRESENTA TAMBIEN UN METODO PARA EL TRATAMIENTO DE NEOPLASMAS SUSCEPTIBLES EN MAMIFEROS UTILIZANDO ESTOS COMPUESTOS DE SULFONILUREA Y LOS PROCESOS PARA LA PRODUCCION DE LOS MISMOS.
ES92311031T 1991-12-20 1992-12-03 Composiciones antitumorales y procedimiento de tratamiento. Expired - Lifetime ES2104853T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/811,483 US5234955A (en) 1991-12-20 1991-12-20 Antitumor compositions and methods of treatment

Publications (1)

Publication Number Publication Date
ES2104853T3 true ES2104853T3 (es) 1997-10-16

Family

ID=25206668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92311031T Expired - Lifetime ES2104853T3 (es) 1991-12-20 1992-12-03 Composiciones antitumorales y procedimiento de tratamiento.

Country Status (9)

Country Link
US (2) US5234955A (es)
EP (1) EP0550157B1 (es)
JP (1) JPH05345755A (es)
AT (1) ATE155776T1 (es)
CA (1) CA2084469A1 (es)
DE (1) DE69221106T2 (es)
DK (1) DK0550157T3 (es)
ES (1) ES2104853T3 (es)
GR (1) GR3024986T3 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
CA2267998A1 (en) * 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment
TW486463B (en) * 1997-10-04 2002-05-11 Dev Center Biotechnology Guanidine derivatives, method for making the same, and anti-cancer composition containing the same
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
ES2272730T3 (es) * 2001-06-15 2007-05-01 Innovent Technology Limited Composicion para el tratamiento de enfermedades que afectan a las pezuñas de los animales.
WO2011009059A2 (en) * 2009-07-17 2011-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating or preventing cancer
US9341238B2 (en) 2012-06-15 2016-05-17 Gkn Driveline North America, Inc. Power transfer unit straddle mount ring gear disconnect

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3083207A (en) * 1963-03-26 Indolinesulfonylureas
DE1144259B (de) * 1956-05-29 1963-02-28 Hoechst Ag Verfahren zur Herstellung von Sulfonylharnstoffen
DE1159937B (de) * 1960-06-29 1963-12-27 Heyden Chem Fab Verfahren zur Herstellung von Hydrindensulfonylharnstoffen
US3097242A (en) * 1960-06-29 1963-07-09 Olin Mathieson Hydrindene sulfonylureas
US3102121A (en) * 1961-06-29 1963-08-27 Olin Mathieson Novel cumaransulfonylureas and 2,3-dihydrothionaphthenesulfonylureas
DE1240866B (de) * 1961-06-29 1967-05-24 Heyden Chem Fab Verfahren zur Herstellung von Indolin-6-sulfonylharnstoffen
NL295122A (es) * 1962-04-11
US3849110A (en) * 1963-01-07 1974-11-19 Lilly Co Eli Herbicidal method employing aryl-sulfonylureas or salts thereof
US3736122A (en) * 1969-04-10 1973-05-29 C Tung Method of controlling plant growth
AU1862083A (en) * 1982-09-02 1984-03-08 Duphar International Research B.V. Tumor growth inhibitors
CA1208561A (en) * 1984-01-19 1986-07-29 Marius S. Brouwer Pharmaceutical compositions containing benzoylurea compounds
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
GR862353B (en) * 1985-09-23 1987-01-19 Lilly Co Eli Anti-tumor method and compounds
CA1331464C (en) * 1987-05-12 1994-08-16 Eli Lilly And Company Anti-tumor method and compounds

Also Published As

Publication number Publication date
US5354778A (en) 1994-10-11
US5234955A (en) 1993-08-10
EP0550157A1 (en) 1993-07-07
JPH05345755A (ja) 1993-12-27
DE69221106D1 (de) 1997-08-28
CA2084469A1 (en) 1993-06-21
DE69221106T2 (de) 1997-12-11
EP0550157B1 (en) 1997-07-23
GR3024986T3 (en) 1998-01-30
DK0550157T3 (da) 1997-12-01
ATE155776T1 (de) 1997-08-15

Similar Documents

Publication Publication Date Title
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
FI922481A0 (fi) Heterocykliska derivat.
WO2001098277A3 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ES2181853T3 (es) Tratamiento del tinnitus empleando agentes neuroprotectores.
DE69429591D1 (de) Therapeutisch wirksame Verbindungen
ES2104853T3 (es) Composiciones antitumorales y procedimiento de tratamiento.
DE60102171D1 (de) Ketolidantibiotika
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
DK213290D0 (da) Treatment of cerebrovascular disorders
HUT63837A (en) Process for producing dibenz/b,f//1,4/oxazepin-11(10oh)-ones as active ingredients eliminating multiple drug resistance
FI902632A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-substitoitujen 5,11-dihydrodibentso/b,e//1,4/tiatsepiinijohdannaisten valmistamiseksi sekä menetelmässä käyttökelpoisia välituotteita
DK469687A (da) Derivater af 4,5-dihydrooxazoler og fremgangsmaade til fremstilling af saadanne derivater.
PT1167376E (pt) Antibioticos macrolidos
EA200001028A1 (ru) Производные 2"-деоксигигромицина
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
BR9405997A (pt) Composições antitumorais e métodos de tratamento
EA200100444A1 (ru) Производные гигромицина а в качестве антибактериальных агентов
DE69413545D1 (de) Thiazole mit antiviraler wirkung
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
DE68909961D1 (de) 2-Aminoacetamid Derivate.
ES501744A0 (es) Procedimiento para la obtencion de bis (fenoxiacetatos sus- tituidos)de n-alcohil-dialcanolaminas
JO1648B1 (en) Nitrogen compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 550157

Country of ref document: ES